NasdaqGS:UPB
NasdaqGS:UPBBiotechs

Can Upstream Bio's (UPB) Rising Losses Outpace Revenue Growth in Its Long-Term Strategy?

Upstream Bio, Inc. recently announced its second quarter and first half 2025 results, reporting sales of US$937,000 for the quarter and a net loss of US$39.97 million, both higher than the previous year. While sales rose compared to the prior year, the company’s losses increased sharply, highlighting the ongoing balance between revenue growth and ongoing costs. We’ll explore how the increased losses despite sales growth could shape Upstream Bio’s investment narrative going forward. The end...
NYSE:INVX
NYSE:INVXEnergy Services

How Rising Revenue but Lower EPS at Innovex International (INVX) Has Changed Its Investment Story

Innovex International reported second quarter 2025 results, with sales rising to US$224.23 million and net income reaching US$15.35 million, and issued third quarter revenue guidance between US$230 million and US$240 million. An important detail is that, while sales and net income improved, both basic and diluted earnings per share from continuing operations were lower than the prior year, pointing to shifts in profitability per share. We'll explore how the company's updated revenue guidance...
NYSE:PLNT
NYSE:PLNTHospitality

Will Strong Q2 Results and New Club Expansion Plans Change Planet Fitness' (PLNT) Growth Narrative?

Planet Fitness, Inc. recently reported its second quarter 2025 results, with sales rising to US$138.99 million and net income increasing to US$58.02 million compared to the prior year, alongside announcing plans for 130 to 140 new equipment placements and 160 to 170 new franchisee-owned club openings. This combination of strong financial results and ambitious expansion plans points to confidence in business momentum and ongoing growth across the Planet Fitness system. We'll explore how...
NYSE:MMS
NYSE:MMSProfessional Services

Maximus (MMS) Is Up 14.4% After Upgraded Revenue Guidance and Strong Q3 Earnings – What’s Changed

Earlier this month, Maximus, Inc. reported third quarter 2025 earnings showing higher sales and net income, and also raised its full-year revenue guidance to between US$5.38 billion and US$5.48 billion. This combination of improved financial performance and upgraded outlook highlights management’s confidence in ongoing growth and the strength of demand for Maximus’ government-focused services. With full-year revenue guidance raised, we'll explore how Maximus' updated outlook impacts its...
NasdaqCM:CMPX
NasdaqCM:CMPXBiotechs

Compass Therapeutics And 2 Other Promising Penny Stocks To Consider

As the U.S. stock market continues its rally, with major indices like the S&P 500 and Nasdaq reaching new all-time highs, investors are exploring diverse opportunities to capitalize on this momentum. Penny stocks, often perceived as relics of past trading days, still present intriguing prospects when backed by robust financials. In this article, we explore three penny stocks that stand out for their balance sheet strength and potential for significant returns, offering investors a chance to...